[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335111-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335111-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multi-omics-analysis-identifies-repurposing-bortezomib-in-the-treatment-of-kidney-nervous-system-and-hematological-cancers","Multi‑omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers","","Repurposing FDA-approved drugs offers a fast, cost-effective alternative to de novo development. This work identifies genes linked to bortezomib sensitivity, predicts cancer types that may benefit, and evaluates bortezomib’s mechanism of action across breast cancer (BT-474, ZR-75-30), melanoma (A-375), and glioblastoma (A-172) cells in vitro. Cancer cell lines from blood, kidney, nervous system, and skin show higher sensitivity than other organ systems. Although β5 inhibition occurs in all tested lines, cell-cycle arrest is limited to G2/M phase and apoptosis is observed in A-375 and A-172 after 24 h. Genomic and transcriptomic analyses reveal 33 resistance-associated genes, yielding biomarkers and candidate indications.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multi-omics-analysis-identifies-repurposing-bortezomib-in-the-treatment-of-kidney-nervous-system-and-hematological-cancers/335111/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multi-omics-analysis-identifies-repurposing-bortezomib-in-the-treatment-of-kidney-nervous-system-and-hematological-cancers/335111.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the multi-omics analysis in this study?","Question",{"text":63,"@type":64},"To identify genes linked to bortezomib sensitivity, predict cancer types that may benefit, and evaluate bortezomib’s mechanism of action across selected cancer cell models in vitro.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which cancer cell types were tested for bortezomib effects?",{"text":68,"@type":64},"Breast cancer (BT-474 and ZR-75-30), melanoma (A-375), and glioblastoma (A-172) cells, along with cancer cell lines derived from blood, kidney, nervous system, and skin.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study show about bortezomib’s mechanism of action?",{"text":72,"@type":64},"Bortezomib effectively inhibits the β5 catalytic site in all tested cell lines, while cell-cycle arrest is induced in G2/M phase and apoptosis is specifically observed in A-375 and A-172 after 24 hours.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335111,1790146528,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMulti‑omics analysis identifies repurposing bortezomib in the treatment of kidney‑, nervous system‑, and hematological cancers  \nPeter Larsson1,2*, Maxim Olsson3, Sithumini Sarathchandra3, Anna Fäldt Beding1,4, Eva Forssell‑Aronsson2,5,6, Anikó Kovács7, Per Karlsson1,8, Khalil Helou1,2 &  \nToshima Z. Parris1,2  \nRepurposing of FDA‑approved drugs is a quick and cost‑effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and evaluate the mechanism‑of‑action of bortezomibin breast cancer (BT‑474 and ZR‑75–30), melanoma (A‑375), and glioblastoma (A‑172) cells in vitro. Cancer cell lines derived from cancers ofthe blood, kidney, nervous system, and skin were found to be significantly more sensitive to bortezomib than other organ systems. The in vitro studies confirmed that although bortezomib effectively inhibited the β5 catalytic site in all four cell lines, cell cycle arrest was only induced inG2/M phase and apoptosis inA‑375 andA‑172 after 24h. The genomic and transcriptomic analyses identified 33 genes (e.g. ALDH18A1, ATAD2) associated with bortezomib resistance. Taken together, we identified biomarkers predictive of bortezomib sensitivity and cancer types that might benefit from treatment with bortezomib.  \nKeywords Drug repurposing, Proteasome inhibitor, Bortezomib, Gene expression profiling, Mutation profiling, Cancer, Pharmacology  \nThe 26S proteasome is a large barrel-shaped protein complex, consisting of up to three subunits (one 20S and one or two 19S subunits) and three catalytic sites (β1 [caspase-like], β2 [trypsin-like], and β5 [chymotrypsinlike]), that is tasked with degrading up to 90% of temporary and misfolded, ubiquitinated proteins in the cell1–4. Proteolysis is necessary to prevent protein accumulation, provide the cell with new building blocks (amino acids) for new proteins, regulate certain cellular processes (e.g. cell cycle, immune response and apoptosis), and control protein quality5,6. Although abnormally high proteasome activity is found in neoplastic tissue, cancer stem cells or cancer cells with stem cell characteristics have been associated with decreased proteasome activity7,8. Elevated proteasome activity is caused by several factors, including mutations resulting in an accumulation of misfolded proteins in the cell9. Inhibition of proteasome catalytic activity can in turn lead to accumulation of proteins, thereby resulting in the disruption of key cellular processes, a reduced amount of free amino acids available for protein synthesis, cell cycle arrest, and ultimately cell death10, 11.  \nBortezomib (VELCADE®, formerly PS-341) was the first proteasome inhibitor to pass clinical trials and be approved by US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line  \n1Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 3Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden. 4Department of Oncology, Southern Älvsborg Hospital, Borås, Sweden. 5Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 6Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden. 7Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden. 8Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. *email: [peter.larsson.3@gu.se](peter.larsson.3@gu.se)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \ntreatment for patients diagnosed with multiple myeloma12. Bortezomib and ","cbCaindUl4VnWEOj","https://ap.wps.com/l/cbCaindUl4VnWEOj","pdf",3602210,"English","# Abstract\n## Drug repurposing rationale and study goals\n## Proteasome biology and rationale for inhibition\n## Bortezomib background and clinical context\n## Study findings across cancer types","[{\"question\":\"What is the main purpose of the multi-omics analysis in this study?\",\"answer\":\"To identify genes linked to bortezomib sensitivity, predict cancer types that may benefit, and evaluate bortezomib’s mechanism of action across selected cancer cell models in vitro.\"},{\"question\":\"Which cancer cell types were tested for bortezomib effects?\",\"answer\":\"Breast cancer (BT-474 and ZR-75-30), melanoma (A-375), and glioblastoma (A-172) cells, along with cancer cell lines derived from blood, kidney, nervous system, and skin.\"},{\"question\":\"What did the study show about bortezomib’s mechanism of action?\",\"answer\":\"Bortezomib effectively inhibits the β5 catalytic site in all tested cell lines, while cell-cycle arrest is induced in G2/M phase and apoptosis is specifically observed in A-375 and A-172 after 24 hours.\"}]","Multi‑omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers | PDF",1790009696]